Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior

Behavioural Brain Research

Volumn 192, Issue 1, 2008, Pages 106-113

  Selkoe, Dennis J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Alzheimer's disease; Amyloid protein; Oligomers; Synaptic plasticity

Indexed keywords

AMYLOID BETA PROTEIN; N METHYL DEXTRO ASPARTIC ACID; OLIGOMER;

BEHAVIOR; BONE DENSITY; DENDRITE; HIPPOCAMPUS; LONG TERM POTENTIATION; MEMORY; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; CEREBRAL CORTEX; DENDRITIC SPINES; HUMANS; LONG-TERM POTENTIATION; MODELS, NEUROLOGICAL; NEURONAL PLASTICITY; POLYMERS; SYNAPSES; SYNAPTIC TRANSMISSION;

EID: 44549087765     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbr.2008.02.016     Document Type: Review

References (72)

1. Bitan G., Kirkitadze M.D., Lomakin A., Vollers S.S., Benedek G.B., and Teplow D.B. Amyloid β-protein (Aβ) assembly: Aβ 40 and Aβ 42 oligomerize through distinct pathways. Proc Natl Acad Sci USA 100 (2003) 330-335
2. Bitan G., and Teplow D.B. Preparation of aggregate-free, low molecular weight amyloid-beta for assembly and toxicity assays. Methods Mol Biol 299 (2005) 3-9
3. Bloodgood B.L., and Sabatini B.L. Nonlinear regulation of unitary synaptic signals by CaV(2.3) voltage-sensitive calcium channels located in dendritic spines. Neuron 53 (2007) 249-260
4. Bookheimer S.Y., Strojwas M.H., Cohen M.S., Saunders A.M., Pericak-Vance M.A., Mazziotta J.C., et al. Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med 343 (2000) 450-456
5. Busciglio J., Gabuzda D.H., Matsudaira P., and Yankner B.A. Generation of β-amyloid in the secretory pathway in neuronal and nonneuronal cells. Proc Natl Acad Sci USA 90 (1993) 2092-2096
6. Caughey B., and Lansbur P.T. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 26 (2003) 267-298
7. Chen Q.S., Wei W.Z., Shimahara T., and Xie C.-W. Alzheimer Amyloid beta-peptide inhibits the late phase of long-term potentiation through calcineurin-dependent mechanisms in the hippocampal dentate gyrus. Neurobiol Learn Mem 77 (2002) 354-371
8. Cleary J., Hittner J.M., Semotuk M., Mantyh P., and O'Hare E. Beta-amyloid(1-40) effects on behavior and memory. Brain Res 682 (1995) 69-74
9. Cleary J.P., Walsh D., Hofmeister J.J., Shankar G.M., Kuskowski M.A., Selkoe D.J., et al. Natural oligomers of the amyloid β-protein specifically disrupt cognitive function. Nat Neurosci 8 (2005) 79-84
10. Cummings B.J., Pike C.J., Shankle R., and Cotman C.W. Beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease. Neurobiol Aging 17 (1996) 921-933
11. Davies C.A., Mann D.M., Sumpter P.Q., and Yates P.O. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J Neurol Sci 78 (1987) 151-164
12. Dodart J.C., Bales K.R., Gannon K.S., Greene S.J., DeMattos R.B., Mathis C., et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 5 (2002) 452-457
13. Engert F., and Bonhoeffer T. Dendritic spine changes associated with hippocampal long-term synaptic plasticity. Nature 399 (1999) 66-70
14. Enya M., Morishima-Kawashima M., Yoshimura M., Shinkai Y., Kusui K., Khan K., et al. Appearance of sodium dodecyl sulfate-stable amyloid beta-protein (Abeta) dimer in the cortex during aging. Am J Pathol 154 (1999) 271-279
15. Frautschy S.A., Hu W., Kim P., Miller S.A., Chu T., Harris-White M.E., et al. Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology. Neurobiol Aging 22 (2001) 993-1005
16. Funato H., Enya M., Yoshimura M., Morishima-Kawashima M., and Ihara Y. Presence of sodium dodecyl sulfate-stable amyloid beta-protein dimers in the hippocampus CA1 not exhibiting neurofibrillary tangle formation. Am J Pathol 155 (1999) 23-28
17. Gong Y., Chang L., Viola K.L., Lacor P.N., Lambert M.P., Finch C.E., et al. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA 100 (2003) 10417-10422
18. Gravina S.A., Ho L., Eckman C.B., Long K.E., Otvos L.J., Younkin L.H., et al. Amyloid β protein (Aβ) in Alzheimer's disease brain. J Biol Chem 270 (1995) 7013-7016
19. Haass C., Schlossmacher M., Hung A.Y., Vigo-Pelfrey C., Mellon A., Ostaszewski B., et al. Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature 359 (1992) 322-325
20. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
21. Hardy J.A., and Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 256 (1992) 184-185
22. Harper J.D., Wong S.S., Lieber C.M., and Lansbury Jr. P.T. Observation of metastable Aβ amyloid protofibrils by atomic force microscopy. Chem Biol 4 (1997) 119-125
23. Hartley D., Walsh D.M., Ye C.P., Diehl T., Vasquez S., Vassilev P.M., et al. Protofibrillar intermediates of amyloid β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 19 (1999) 8876-8884
24. Hsieh H., Boehm J., Sato C., Iwatsubo T., Tomita T., Sisodia S., et al. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 52 (2006) 831-843
25. Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina H., and Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 13 (1994) 45-53
26. Jourdain P., Fukunaga K., and Muller D. Calcium/calmodulin-dependent protein kinase II contributes to activity-dependent filopodia growth and spine formation. J Neurosci 23 (2003) 10645-10649
27. Kawarabayashi T., Shoji M., Younkin L.H., Wen-Lang L., Dickson D.W., Murakami T., et al. Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 24 (2004) 3801-3809
28. Klein W.L., Krafft G.A., and Finch C.E. Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum?. Trends Neurosci 24 (2001) 219-224
29. Klyubin I., Walsh D.M., Lemere C.A., Cullen W.K., Shankar G.M., Betts V., et al. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med 11 (2005) 556-561
30. Kotilinek L.A., Bacskai B., Westerman M., Kawarabayashi T., Younkin L., Hyman B.T., et al. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci 22 (2002) 6331-6335
31. 1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95 (1998) 6448-6453
32. Lashuel H.A., Hartley D., Petre B.M., Walz T., and Lansbury Jr. P.T. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418 (2002) 291
33. Lesne S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440 (2006) 352-357
34. Malenka R.C., and Bear M.F. LTP and LTD: an embarrassment of riches. Neuron 44 (2004) 5-21
35. Maletic-Savatic M., Malinow R., and Svoboda K. Rapid dendritic morphogenesis in CA1 hippocampal dendrites induced by synaptic activity. Science 283 (1999) 1923-1927
36. Masliah E., Mallory M., Alford M., DeTeresa R., Hansen L.A., McKeel Jr. D.W., et al. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology 56 (2001) 127-129
37. Matsuzaki M., Honkura N., Ellis-Davies G.C., and Kasai H. Structural basis of long-term potentiation in single dendritic spines. Nature 429 (2004) 761-766
38. McDonald M.P., Dahl E.E., Overmier J.B., Mantyh P., and Cleary J. Effects of an exogenous beta-amyloid peptide on retention for spatial learning. Behav Neural Biol 62 (1994) 60-67
39. McLaurin J., Kierstead M.E., Brown M.E., Hawkes C.A., Lambermon M.H., Phinney A.L., et al. Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med 12 (2006) 801-808
40. McLean C.A., Cherny R.A., Fraser F.W., Fuller S.J., Smith M.J., Beyreuther K., et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46 (1999) 860-866
41. Mulkey R.M., Endo S., Shenolikar S., and Malenka R.C. Involvement of a calcineurin/inhibitor-1 phosphatase cascade in hippocampal long-term depression. Nature 369 (1994) 486-488
42. Nagerl U.V., Eberhorn N., Cambridge S.B., and Bonhoeffer T. Bidirectional activity-dependent morphological plasticity in hippocampal neurons. Neuron 44 (2004) 759-767
43. Näslund J., Haroutunian V., Mohs R., Davis K., Davies P., Greengard P., et al. Correlation between elevated levels of amyloid β-peptides in the brain and cognitive decline. JAMA 283 (2000) 1571-1577
44. Nicoll R.A., and Malenka R.C. Expression mechanisms underlying NMDA receptor-dependent long-term potentiation. Ann NY Acad Sci 868 (1999) 515-525
45. O'Hare E., Weldon D.T., Mantyh P.W., Ghilardi J.R., Finke M.P., Kuskowski M.A., et al. Delayed behavioral effects following intrahippocampal injection of aggregated A beta (1-42). Brain Res 815 (1999) 1-10
46. Petersen R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., and Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56 (1999) 303-308
47. Podlisny M.B., Ostaszewski B.L., Squazzo S.L., Koo E.H., Rydel R.E., Teplow D.B., et al. Aggregation of secreted amyloid β-protein into SDS-stable oligomers in cell culture. J Biol Chem 270 (1995) 9564-9570
48. Price J.L., and Morris J.C. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 45 (1999) 358-368
49. Roher A.E., Chaney M.O., Kuo Y.-M., Webster S.D., Stine W.B., Haverkamp L.J., et al. Morphology and toxicity of Aβ-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J Biol Chem 271 (1996) 20631-20635
50. N3(p3), in senile plaques. Neuron 14 (1995) 457-466
51. Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., et al. Secreted amyloid b-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2 (1996) 864-870
52. Selkoe D.J. The molecular pathology of Alzheimer's disease. Neuron 6 (1991) 487-498
53. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science 298 (2002) 789-791
54. Seubert P., Vigo-Pelfrey C., Esch F., Lee M., Dovey H., Davis D., et al. Isolation and quantitation of soluble Alzheimer's β-peptide from biological fluids. Nature 359 (1992) 325-327
55. Shankar G.M., Bloodgood B.L., Townsend M., Walsh D.M., Selkoe D.J., and Sabatini B.L. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 27 (2007) 2866-2875
56. Shoji M., Golde T.E., Ghiso J., Cheung T.T., Estus S., Shaffer L.M., et al. Production of the Alzheimer amyloid β protein by normal proteolytic processing. Science 258 (1992) 126-129
57. Small G.W., Ercoli L.M., Silverman D.H., Huang S.C., Komo S., Bookheimer S.Y., et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 97 (2000) 6037-6042
58. Snyder E.M., Nong Y., Almeida C.G., Paul S., Moran T., Choi E.Y., et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nature Neurosci 8 (2005) 1051-1058
59. Sweeney W.A., Luedtke J., McDonald M.P., and Overmier J.B. Intrahippocampal injections of exogenous beta-amyloid induce postdelay errors in an eight-arm radial maze. Neurobiol Learn Mem 68 (1997) 97-101
60. Teplow D.B. Structural and kinetic features of amyloid beta-protein fibrillogenesis. Amyloid 5 (1998) 121-142
61. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30 (1991) 572-580
62. Townsend M., Shankar G.M., Mehta T., Walsh D.M., and Selkoe D.J. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol 572 (2006) 477-492
63. Townsend M., Mehta T., and Selkoe D.J. Soluble amyloid β-protein inhibits specific signal transduction cascds common to the insulin reception pathway. J Biol Chem (2007)
64. Vigo-Pelfrey C., Lee D., Keim P.S., Lieberburg I., and Schenk D. Characterization of β-amyloid peptide from human cerebrospinal fluid. J Neurochem 61 (1993) 1965-1968
65. Walsh D., Klyubin I., Fadeeva J., Cullen W.K., Anwyl R., Wolfe M., et al. Naturally secreted oligomers of the Alzheimer amyloid β-protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416 (2002) 535-539
66. Walsh D.M., Hartley D.M., Kusumoto Y., Fezoui Y., Condron M.M., Lomakin A., et al. Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J Biol Chem 274 (1999) 25945-25952
67. Walsh D.M., Tseng B.P., Rydel R.E., Podlisny M.B., and Selkoe D.J. Detection of intracellular oligomers of amyloid β-protein in cells derived from human brain. Biochemistry 39 (2000) 10831-10839
68. Walsh D.M., Hartley D.M., and Selkoe D.J. The many faces of Aβ: Structures and activity. Curr Med Chem Immun Endoc Metab Agents 3 (2003) 277-291
69. Walsh D.M., Townsend T.M., Podlisny M.B., Shankar G.M., Fadeeva J., El-Agnaf O., et al. Certain inhibitors of synthetic Aβ fibrillogenesis block oligomerization of natural Aβ and thereby rescue long term potentiation. J Neurosci 25 (2005) 2455-2462
70. Wang R., Sweeney D., Gandy S.E., and Sisodia S.S. The profile of soluble amyloid b protein in cultured cell media. Detection and quantificaiton of amyloid β protein and variants by immunoprecipitation-mass spectrometry. J Biol Chem 271 (1996) 31894-31902
71. Xia W., Zhang J., Kholodenko D., Citron M., Podlisny M.B., Teplow D.B., et al. Enhanced production and oligomerization of the 42-residue amyloid b-protein by Chinese hamster ovary cells stably expressing mutant presenilins. J Biol Chem 272 (1997) 7977-7982
72. Zhou Q., Homma K.J., and Poo M.M. Shrinkage of dendritic spines associated with long-term depression of hippocampal synapses. Neuron 44 (2004) 749-757